Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 16/20 | 0.71 |
| ▸ | HTR3E | A5X5Y0 | 6/20 | 0.71 |
| ▸ | HTR3B | O95264 | 6/20 | 0.71 |
| ▸ | HTR3A | P46098 | 6/20 | 0.71 |
| ▸ | HTR3D | Q70Z44 | 6/20 | 0.71 |
| ▸ | HTR3C | Q8WXA8 | 6/20 | 0.71 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4210012 | 1.00 | CHRNA7 (0.71) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL4197233 | 0.89 | CHRNA7 (0.75) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL4197229 | 0.89 | CHRNA7 (0.75) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL7064064 | 0.88 | CHRNA7 (0.73) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| Hydrochloric Acid SCHEMBL7060578 | 0.87 | CHRNA7 (0.72) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL5072542 | 0.86 | CHRNA7 (0.51) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL7003129 | 0.86 | CHRNA7 (0.51) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL6486145 | 0.84 | CHRNA7 (0.67) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL7057819 | 0.84 | CHRNA7 (0.80) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL4195124 | 0.84 | CHRNA7 (1.00) | CHRNA7HTR3EHTR3BHTR3AHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1545537-B9 | ALPHA-7 NICOTINIC RECEPTOR AGONISTS AND STATINS IN COMBINATION | ASTRAZENECA AB (SE) | 2008-08-20 | — | — | EP | claimed |
| US-7214688-B2 | Compounds | ASTRAZENECA AB (SE) | 2007-05-08 | — | — | US | claimed |
| EP-1545537-B1 | ALPHA-7 NICOTINIC RECEPTOR AGONISTS AND STATINS IN COMBINATION | ASTRAZENECA AB (SE) | 2007-04-04 | — | — | EP | claimed |
| US-20060128749-A1 | Compounds | PHILLIPS EIFION | 2006-06-15 | — | — | US | claimed |
| US-20050256146-A1 | Alpha-7 nicotinic receptor agonists and stains in combination | ASTRAZENECA AB (SE) | 2005-11-17 | — | — | US | claimed |
| EP-1545537-A1 | ALPHA-7 NICOTINIC RECEPTOR AGONISTS AND STATINS IN COMBINATION | AstraZeneca AB (SE) | 2005-06-29 | — | — | EP | claimed |
| US-20040259909-A1 | Treatment of fibromyalgia syndrome | ASTRAZENECA AB (SE) | 2004-12-23 | — | — | US | claimed |
| WO-2004019947-A1 | ALPHA-7 NICOTINIC RECEPTOR AGONISTS AND STATINS IN COMBINATION | ASTRAZENECA AB (SE) | 2004-03-11 | — | — | WO | claimed |
| EP-1259508-B1 | NOVEL BIARYLCARBOXAMIDES | ASTRAZENECA AB (SE) | 2003-10-15 | — | — | EP | claimed |
| US-20030008867-A1 | Compounds | ASTRAZENECA AB (SE) | 2003-01-09 | — | — | US | claimed |
| EP-1259508-A1 | NOVEL BIARYLCARBOXAMIDES | AstraZeneca AB (SE) | 2002-11-27 | — | — | EP | claimed |
| WO-2001060821-A1 | NOVEL BIARYLCARBOXAMIDES | ASTRAZENECA AB (SE) | 2001-08-23 | — | — | WO | claimed |
| US-20090192180-A1 | Alpha-7 Nicotinic Receptor Agonists and Statins In Combination | KEITH RICHARD | 2009-07-30 | — | — | US | disclosed |
| US-7491734-B2 | 2-(pyridine-4-yl)-N-(quinuclidin-2-yl)thiazole-4-carboxide nicotinic acetylcholine receptor ligands | ASTRAZENECA AB (SE) | 2009-02-17 | — | — | US | disclosed |
| EP-1545537-B9 | ALPHA-7 NICOTINIC RECEPTOR AGONISTS AND STATINS IN COMBINATION | ASTRAZENECA AB (SE) | 2008-08-20 | — | — | EP | disclosed |
| US-20070149563-A1 | New Compounds | PHILLIPS EIFION | 2007-06-28 | — | — | US | disclosed |
| EP-1259508-B1 | NOVEL BIARYLCARBOXAMIDES | ASTRAZENECA AB (SE) | 2003-10-15 | — | — | EP | disclosed |
| US-20030008867-A1 | Compounds | ASTRAZENECA AB (SE) | 2003-01-09 | — | — | US | disclosed |
| EP-1259508-A1 | NOVEL BIARYLCARBOXAMIDES | AstraZeneca AB (SE) | 2002-11-27 | — | — | EP | disclosed |
| WO-2001060821-A1 | NOVEL BIARYLCARBOXAMIDES | ASTRAZENECA AB (SE) | 2001-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128749-A1 | Compounds | DRD2, DRD1, GRIN2A | CHRNA7 302/4885HTR3E 601/4885HTR3B 753/4885 |
| US-20070149563-A1 | New Compounds | DRD1, DRD2, GRIN2A | CHRNA7 145/4885HTR3E 569/4885HTR3B 682/4885 |
| US-20030008867-A1 | Compounds | DRD2, DRD1, GRIN2A | CHRNA7 209/4885HTR3E 350/4885HTR3B 441/4885 |
| US-20040259909-A1 | Treatment of fibromyalgia syndrome | CHRNA7, CHRNA5, CHRNA10 | CHRNA7 1/4885HTR3E 251/4885HTR3B 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.